EuBiologics

(주)유바이오로직스 · KOSDAQ · 206650 · Industry: Manufacture of medicaments

Key metrics

Earnings

Revenue, Q3 2026₩49.6bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQNot available
Revenue YoYNot available
Operating income, Q3 2026₩21.9bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQNot available
Operating income YoYNot available

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of sharesNot available
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of sharesNot available
Treasury shares cancelled, last 3 months₩4.5bn As of Aug 21, 2026 Source 1 ↗
Treasury shares cancelled (number), last 3 months398,987 shares As of Aug 21, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months, % of sharesNot available
Buyback decided, last 12 months₩6.0bn As of Mar 26, 2026 Source 1 ↗
Buyback decided, last 12 months, % of sharesNot available
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of sharesNot available
Treasury shares cancelled, last 12 months₩4.5bn As of Aug 21, 2026 Source 1 ↗
Treasury shares cancelled (number), last 12 months398,987 shares As of Aug 21, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months, % of sharesNot available

Potential dilution

CB/BW/EB issued, last 12 months₩0 As of Nov 19, 2026
Rights offering new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, % of sharesNot available
Conversion price adjustments, last 12 months0 As of Nov 19, 2026

Supply contracts

Supply contracts, last 12 months₩79.6bn As of Oct 26, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Supply contracts vs prior-year revenue53.3% As of Oct 26, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months4 As of Nov 19, 2026
DART filings, previous 3 months14 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)369,627 shares As of Jul 6, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Open-market buys, last 12 months (amount)₩5.1bn As of Jul 6, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Open-market sells, last 12 months (shares)685 shares As of Apr 28, 2026 Source 1 ↗
Open-market sells, last 12 months (amount)₩9m As of Apr 28, 2026 Source 1 ↗
Net open-market buying, last 12 months (shares)368,942 shares As of Jul 6, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Insiders who bought, last 12 months4 As of Jul 6, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more

Insider transactions (last 12 months)

Open-market buys: 369,627 shares (₩5.1bn). Open-market sells: 685 shares (₩9m). Net open-market buying: +368,942 shares. Insiders who bought: 4.

Trade dateInsider (role)TypeSharesPriceAmount
Jul 6, 2026Heo Tae-yeong (Registered director)Open-market buy+2,000 shares₩8,590₩17m
Jul 3, 2026Heo Tae-yeong (Registered director)Open-market buy+1,000 shares₩8,770₩9m
Jul 2, 2026Heo Tae-yeong (Registered director)Open-market buy+6,000 shares₩8,620₩52m
Apr 28, 2026Shin Yeong-hui (Non-registered officer)Open-market sell-685 shares₩13,640₩9m
Apr 21, 2026Shin Yeong-hui (Non-registered officer)Open-market buy+685 shares₩14,000₩10m
Apr 6, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+29,646 shares₩13,619₩404m
Apr 2, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+60,000 shares₩13,743₩825m
Apr 1, 2026Kim Rak-gi (Non-registered officer)Other (New appointment)+3,366 shares——
Mar 30, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+20,000 shares₩13,935₩279m
Mar 25, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+115,572 shares₩13,900₩1.6bn
Mar 24, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+25,000 shares₩14,159₩354m
Mar 23, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+15,000 shares₩14,218₩213m
Mar 20, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+10,500 shares₩14,268₩150m
Mar 18, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+19,428 shares₩14,465₩281m
Mar 16, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+10,000 shares₩14,830₩148m
Mar 13, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+10,000 shares₩14,877₩149m
Mar 12, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+14,000 shares₩14,274₩200m
Mar 11, 2026BioNote, Inc. (10%+ shareholder)Open-market buy+20,796 shares₩13,786₩287m
Jan 28, 2026Jeon Dong-un (Non-registered officer)Other (Stock option exercise)+10,000 shares₩6,440₩64m
Jan 28, 2026Shin Jeong-seop (Non-registered officer)Other (Stock option exercise)+10,000 shares₩6,080₩61m
Jan 28, 2026Jang Jae-seon (Non-registered officer)Other (Stock option exercise)+5,000 shares₩6,080₩30m
Jan 2, 2026Baek Yeong-ok (Registered director)Open-market buy+10,000 shares₩11,695₩117m
Nov 27, 2025Tae Yeong-jin (Non-registered officer)Other (Stock option exercise)+25,000 shares₩6,440₩161m

Annual financials

YearRevenueOperating income
2025₩149.2bn₩60.7bn
2024₩96.0bn₩34.3bn
2023₩69.4bn₩7.7bn

Filing timeline